Views
5 years ago

42 - E Zaidel y col. - Junio 2018

  • Text
  • Glucagon
  • Peptido
  • Ii
  • Glucosa
  • Sodio
  • Glucosa
  • Zaidel
  • Zaidel
  • Elfman
  • Elfman
  • Vecchio
  • Vecchio
  • Diabetes
  • Eventos
  • Cardiovascular
  • Placebo
  • Ensayos
  • Mortalidad
Nuevos fármacos para la diabetes - Dr. Ezequiel Zaidel, Dra. Melisa Elfman, Dr. Augusto Vecchio

considerarse.

considerarse. Finalmente, se destaca la reciente incorporación de una tecnología que permite administrar al semaglutide por vía oral (de 2.5 a 20 mg) con sodio-n-hidroxibenzoilamino-caprilato, o SNAC, lo que evita el clivaje proteolítico en la luz intestinal y permite su absorción paracelular. Conclusiones En esta revisión demostramos la explosión que se observó en la investigación clínica acerca de la farmacoterapia de la diabetes tipo 2. La reducción de la glucemia y de la hemoglobina glicosilada ya se habían relacionado con reducción de eventos, principalmente microvasculares, pero los objetivos terapéuticos de la diabetes cambiaron: la intención es reducir los eventos cardiovasculares, y tanto los GLP-1ra (parenterales) como los SGLT2i (orales) demostraron ser eficaces en este aspecto. Bibliografía sugerida • Zinman B, Wanner C, Lachin JM, et al. EMPA REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128. • Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. • Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262–274. • Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUT- COME(R) trial. Eur Heart J. 2016;37(19):1526–34. Garg SK, Henry RR, Banks P, et al.: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; doi: 10.1056/NEJMoa1708337. • Cingolani H.E., Ennis I.L. Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation. 2007; 115: 1090–1100. • Kosiborod M, Cavender MA, Fu AZ, et al.; CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium- Glucose Cotransporter-2 Inhibitors). Circulation 2017;136:249–259. • Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol 2018;71:2628–39. • Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab 2017;19:831–841. • Di Girolamo G, Tamez PAL, Tamez PHE. (2008). Inhibidores de la dipeptidil peptidasa-4: farmacodinamia, farmacocinética y seguridad. Med Int Mex 2008; 24 (2), 142-147. • Center for Drug Evaluation and Research. (n.d.). Drug Safety and Availability - La FDA advierte que el uso de inhibidores de la DPP-4 para la diabetes de tipo 2 puede causar dolor articular intenso. Retrieved February 13, 2018, from https://www.fda.gov/Drugs/DrugSafety/ucm507971.htm • Mishriky B.M., Cummings D.M., Tanenberg R.J. (2015). The Efficacy and Safety of DPP4 Inhibitors compared to Sulfonylureas as add-on Therapy to Metformin in Patients with Type 2 diabetes: a Systematic Review and Meta-analysis, Diabetes Research and Clinical Practice2015; 109 (2), 378-388. • Karagiannis T., Paschos P., Paletas K., Matthews D.R., Tsapas A. (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369. • Monami M., Lamanna C., Desideri C.M., Mannucci E. (2012).DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. Adv Ther 2012; 29(1):14-25. • Zhang X., Zhao Q. (2016). Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hypertension 2016, 34:167–175. • White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., Perez A.T., Fleck P.R., Mehta C.R., Kupfer S., Wilson C., Cushman W.C., Zannad F. (20013). Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med 2013; 369:1327-1335. • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. • Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, Keith D. Kaufman, Joerg Koglin, Scott Korn, John M. Lachin, Darren K. McGuire, Michael J. Pencina, Eberhard Standl, Peter P. Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D. Peterson, Rury R. Holman. (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373:232-242. • Scirica B.M., Bhatt D.L., Braunwald E., Steg G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mozenson O., McGuire D.K., Ray K.K., Leiter L.A., Raz I. (2013). Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369:1317-1326. • Willemen M.J., Mantel-Teeuwisse A.K., Straus S.M., Meyboom R.H., Egberts T.C., Leufkens H.G. (2011) Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase. Diabetes Care 34 (2); 369–374. • Wang Q., Long M., Qu H., Shen R., Zhang R., Xu J., Xion X., Wang H., Zheng H. (2018). DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Diabetes Research vol. 2018, Article ID 5308582, 1-10. • Egan A.G., Blind E., Dunder K., de Graeff P.A., Hummer B.T., Bourcier T., Rosebraugh C. (2014). Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment. N Engl J Med 2014; 370:794-797. Abe M., Okada K. (2015). DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice. Nitta K (ed): Chronic Kidney Diseases - Recent Advances in Clinical and Basic Research. Contrib Nephrol. Basel Karger 2015; 185: 98-115. • Panchapakesan U., Pollock C. (2015) The role of dipeptidyl peptidase – 4 inhibitors in diabetic kidney disease. Front. Immunol 2015; 6:443. • Guo W.Q., Li L., Su Q., Dai W.R., Ye Z.L. (2017) Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis. Value in Health 2017; 20 (10), 1427 – 1430. • Pinto L.C., Rados D.V., Barkan S.S., Leitão C.B., Gross J.L. (2018). Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A metaanalysis with trial sequential analysis. Scientific Reports (2018) 8; 782, 1-6. • Pi-Sunyer X., Astrup A., Fujioka K., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. • Nauck M., Weinstock R. S., Umpierrez G. E., Guerci B., Skrivanek Z., Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes Care. 2014;37(8):2149–2158. • Home P. D., Shamanna P., Stewart M., et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes, Obesity and Metabolism. 2015;17(2):179–187. • Pfeffer M., Claggett B., Diaz R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. • Marso S., Daniels G., Brown-Frandsen K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. • Marso S. P., Bain S. C., Consoli A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016:1–1175. • Holman R. R., Bethel M. A., Mentz R. J., et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;375(19):1834–1844. • Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2017;318(15):1460-1470. 14 | Editorial Sciens

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015